SMS Pharmaceuticals Announces Financial Results for FY 2026 and Recommends Dividend
SMS Pharmaceuticals Limited announced significant operational and financial updates following its Board of Directors meeting held on May 22, 2026. The Board reviewed and approved the audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2026.The Company also recommended a Final Dividend for the financial year 2025-26 and approved changes related to corporate structure and governance, including the shifting of its registered office and the reappointment of various statutory auditors.
Financial Performance and Dividend Recommendation
The Board reviewed the audited financial performance, noting that the Statutory Auditors have issued an 'Unmodified Opinion' on the Company's Standalone and Consolidated Financial Statements for the year ended March 31, 2026.In a key shareholder action, the Board recommended a Final Dividend of 0.40 Paise (40%) per equity share, which has a face value of ₹1 each, for the financial year 2025-26. This dividend is subject to approval by the members at the ensuing Annual General Meeting (AGM).
The key audited financial highlights (in ₹ Lakhs) show substantial revenue performance:
| Particulars | Quarter ended 31-03-2026 (Standalone) | Year ended 31-03-2026 (Standalone) |
|---|---|---|
| Total Income | 24,052.19 | 89,522.48 |
| Total Expenses | 21,347.63 | 77,895.35 |
| Net Profit after Tax | 2,092.09 | 8,760.93 |
The Consolidated Standalone financial results also provided detailed figures for the quarter and year ended March 31, 2026:
| Particulars | Quarter ended 31-03-2026 (Consolidated) | Year ended 31-03-2026 (Consolidated) |
|---|---|---|
| Total Income | 24,052.19 | 89,522.48 |
| Total Expenses | 21,345.51 | 77,858.72 |
| Net Profit after Tax | 2,096.45 | 8,799.79 |
The audited Standalone Balance Sheet as of March 31, 2026, showed a total asset base of 1,38,100.04 lakh and total equity and liabilities of 1,38,100.04 lakh. The total assets recorded as of March 31, 2025, were 1,18,610.18 lakh.
Governance and Operational Updates
During the board meeting, SMS Pharmaceuticals Limited also approved critical changes concerning its corporate setup and audit functions.Registered Office Shift: The Company approved shifting its Registered Office. The new address will be 8th Floor, Trendset Jayabheri Connect, Kondapur, Serilingampally, Hyderabad- 500084, Rangareddy Dist., Telangana, India. This move is effective from May 25, 2026, and remains within the local limits of the Hyderabad city.
Auditor Appointments: The Board of Directors approved the following appointments for the Financial Year 2026-27:
1. Cost Auditor: M/s. Annapragada & Co., Cost Accountants (formerly known as M/s. Harshitha Annapragada & Co.).
2. Internal Auditor: M/s. Adusumilli & Associates, Chartered Accountants, were re-appointed as Internal Auditors.
Financial Position Summary (As of March 31, 2026)
The audited Standalone Balance Sheet provides a clear view of the Company's assets and liabilities. Total Assets stand at 1,38,100.04 lakh, comprising Non-Current Assets of 74,443.24 lakh and Current Assets of 63,656.80 lakh.Key components of the Standalone financial statements include:
| Particulars | As at 31-03-2026 (Audited) | As at 31.03.2025 (Audited) |
|---|---|---|
| Total Assets | 1,38,100.04 | 1,18,610.18 |
| Shareholders' Funds | 80,478.69 | 67,306.97 |
| Total Equity and Liabilities | 1,38,100.04 | 1,18,610.18 |
In the cash flow statement, Net Cash Inflow from Operating Activities for the year ended March 31, 2026, was 6,068.14 lakh, reaching a Cash and Cash Equivalents balance of 4,578.15 lakh at period end.
SMSPHARMA Stock Price Movement
As of 2:25 PM, shares of SMS Pharmaceuticals Limited are slipping by 7.68% in live trading, currently holding at ₹393.15. The equity volume is robust, with 907,006 shares traded, indicating sustained selling pressure in the pharmaceutical sector.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: